{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2023,10,10]],"date-time":"2023-10-10T05:02:41Z","timestamp":1696914161825},"reference-count":32,"publisher":"Wiley","issue":"5","license":[{"start":{"date-parts":[[2005,8,16]],"date-time":"2005-08-16T00:00:00Z","timestamp":1124150400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Mycoses"],"published-print":{"date-parts":[[2005,9]]},"abstract":"<jats:title>Summary<\/jats:title><jats:p>The <jats:italic>in vitro<\/jats:italic> susceptibility of 29 clinical isolates of <jats:italic>Cryptococcus neoformans<\/jats:italic> to fluconazole, miconazole, itraconazole, ketoconazole, flucytosine, nystatin and amphotericin B was tested by broth and colorimetric microdilution methods. Most of the isolates showed uniform patterns of susceptibility to the used antifungal agents. Only three isolates exhibited resistance [fourfold or greater rise in the minimum inhibitory concentrations (MICs)] to the tested antifungal drugs. The MIC<jats:sub>50<\/jats:sub> and MIC<jats:sub>90<\/jats:sub> were 0.5\u20138\u2003mg\u2003l<jats:sup>\u22121<\/jats:sup> for 5\u2010flucytosine, 0.2\u20138.25\u2003mg\u2003l<jats:sup>\u22121<\/jats:sup> for nystatin, 0.5\u201316\u2003mg\u2003l<jats:sup>\u22121<\/jats:sup> for fluconazole and 0.2\u201312.5\u2003mg\u2003l<jats:sup>\u22121<\/jats:sup> for miconazole. However, MIC<jats:sub>50<\/jats:sub> and MIC<jats:sub>90<\/jats:sub> were in narrow range for the clinical yeast isolates in both methods used and showed 0.5\u20131\u2003mg\u2003l<jats:sup>\u22121<\/jats:sup> for amphotericin B and 0.016\u20130.25\u2003mg\u2003l<jats:sup>\u22121<\/jats:sup> for both ketoconazole and itraconazole. The combination of fluconazole plus flucytosine showed greater synergistic and fungicidal activity compared with that of fluconazole plus amphotericin B or the use of individual drugs.<\/jats:p>","DOI":"10.1111\/j.1439-0507.2005.01137.x","type":"journal-article","created":{"date-parts":[[2005,8,16]],"date-time":"2005-08-16T13:39:58Z","timestamp":1124199598000},"page":"327-332","source":"Crossref","is-referenced-by-count":5,"title":["<i>In vitro<\/i> susceptibility of <i>Cryptococcus neoformans<\/i> clinical isolates from Egypt to seven antifungal drugs"],"prefix":"10.1111","volume":"48","author":[{"given":"Hassan A.","family":"Abdel\u2010Salam","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2005,8,16]]},"reference":[{"key":"e_1_2_5_2_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.48.1.333-336.2004"},{"key":"e_1_2_5_3_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM198909213211205"},{"key":"e_1_2_5_4_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.39.9.1907"},{"key":"e_1_2_5_5_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/46.6.997"},{"key":"e_1_2_5_6_2","doi-asserted-by":"crossref","first-page":"2817","DOI":"10.1128\/JCM.36.10.2817-2822.1998","article-title":"Detection of resistance to amphotericin B among C. neoformans clinical isolates: performances of three different media assessed by using Etest and National Committee for Clinical Laboratory Standards M27\u2010A methodologies","volume":"36","author":"Lozano C","year":"1998","journal-title":"J Clin Microbiol"},{"key":"e_1_2_5_7_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.45.11.3065-3069.2001"},{"key":"e_1_2_5_8_2","doi-asserted-by":"publisher","DOI":"10.1093\/clinids\/12.2.308"},{"key":"e_1_2_5_9_2","doi-asserted-by":"crossref","first-page":"1370","DOI":"10.1128\/jcm.31.5.1370-1372.1993","article-title":"Two\u2010site comparison of broth microdilution and semisolid agar dilution methods for susceptibility testing of C. neoformans in three media","volume":"31","author":"Anaisse ER","year":"1993","journal-title":"J Clin Microbiol"},{"key":"e_1_2_5_10_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/42.4.439"},{"key":"e_1_2_5_11_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.37.6.1383"},{"key":"e_1_2_5_12_2","doi-asserted-by":"publisher","DOI":"10.1007\/BF02930967"},{"key":"e_1_2_5_13_2","doi-asserted-by":"crossref","first-page":"822","DOI":"10.1128\/AAC.40.3.822","article-title":"In vitro susceptibilities of clinical and environmental isolates of C. neoformans to five antifungal drugs","volume":"40","author":"Franzot S","year":"1996","journal-title":"Antimicrob Agents Chemother"},{"key":"e_1_2_5_14_2","doi-asserted-by":"crossref","first-page":"2874","DOI":"10.1128\/JCM.36.10.2874-2876.1998","article-title":"Fluconazole susceptibility testing of C. neoformans: comparison of two broth microdilution methods and clinical correlates among isolates from Ugandan AIDS patients","volume":"36","author":"Jessup C","year":"1998","journal-title":"J Clin Microbiol"},{"key":"e_1_2_5_15_2","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1128\/AAC.42.2.471","article-title":"In vitro comparative efficacy of voriconazole and itraconazole against fluconazole susceptible and resistant C. neoformans isolates","volume":"42","author":"Nguyen MH","year":"1998","journal-title":"Antimicrob Agents Chemother"},{"key":"e_1_2_5_16_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1439-0507.2003.00872.x"},{"key":"e_1_2_5_17_2","volume-title":"Reference Method for Broth Dilution Antifungal Susceptibility of Yeasts: Approved Standard. NCCLS Document M27\u2010A","author":"National Committee for Clinical Laboratory Standards","year":"1997"},{"key":"e_1_2_5_18_2","doi-asserted-by":"crossref","first-page":"748","DOI":"10.1128\/AAC.41.4.748","article-title":"Fluconazole tolerance in clinical isolates of C. neoformans","volume":"41","author":"Venkateswarlu K","year":"1997","journal-title":"J Antimicrob Chemother"},{"key":"e_1_2_5_19_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/42.2.217"},{"key":"e_1_2_5_20_2","doi-asserted-by":"publisher","DOI":"10.1006\/bbrc.1995.1272"},{"key":"e_1_2_5_21_2","doi-asserted-by":"publisher","DOI":"10.1179\/joc.2003.15.2.124"},{"key":"e_1_2_5_22_2","doi-asserted-by":"publisher","DOI":"10.1093\/clinids\/22.2.322"},{"key":"e_1_2_5_23_2","doi-asserted-by":"crossref","first-page":"1330","DOI":"10.1128\/JCM.36.5.1330-1332.1998","article-title":"Comparative evaluation of National Committee for Clinical Laboratory Standards broth macrodilution and agar dilution screening methods for testing fluconazole susceptibility of C. neoformans","volume":"36","author":"Kirkpatrick WR","year":"1998","journal-title":"J Clin Micrbiol"},{"key":"e_1_2_5_24_2","doi-asserted-by":"crossref","first-page":"2881","DOI":"10.1128\/jcm.30.11.2881-2886.1992","article-title":"Susceptibility testing of C. neoformans: a microdilution technique","volume":"30","author":"Ghannum MA","year":"1992","journal-title":"J Clin Microbiol"},{"key":"e_1_2_5_25_2","doi-asserted-by":"crossref","first-page":"2494","DOI":"10.1128\/jcm.32.10.2494-2500.1994","article-title":"Comparative study of broth macrodilution and microdilution techniques for in vitro antifungal susceptibility testing of yeasts by using the National Committee for Clinical Laboratory Standards\u2019 proposed standard","volume":"32","author":"Barchiesi A","year":"1994","journal-title":"J Clin Microbiol"},{"key":"e_1_2_5_26_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/44.1.65"},{"key":"e_1_2_5_27_2","doi-asserted-by":"publisher","DOI":"10.1128\/JCM.38.9.3457-3459.2000"},{"key":"e_1_2_5_28_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/46.5.815"},{"key":"e_1_2_5_29_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/45.2.239"},{"key":"e_1_2_5_30_2","first-page":"192","author":"Mengoli C","year":"1991","journal-title":"Cryptococcus neoformans Meningitis in AIDS: In vitro Susceptibility to Antifungal Drugs"},{"key":"e_1_2_5_31_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.46.2.367-370.2002"},{"key":"e_1_2_5_32_2","doi-asserted-by":"publisher","DOI":"10.1080\/02681219380000581"},{"key":"e_1_2_5_33_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/45.5.645"}],"container-title":["Mycoses"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1439-0507.2005.01137.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/j.1439-0507.2005.01137.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,9]],"date-time":"2023-10-09T21:15:20Z","timestamp":1696886120000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/j.1439-0507.2005.01137.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2005,8,16]]},"references-count":32,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2005,9]]}},"alternative-id":["10.1111\/j.1439-0507.2005.01137.x"],"URL":"https:\/\/doi.org\/10.1111\/j.1439-0507.2005.01137.x","archive":["Portico"],"relation":{},"ISSN":["0933-7407","1439-0507"],"issn-type":[{"value":"0933-7407","type":"print"},{"value":"1439-0507","type":"electronic"}],"subject":[],"published":{"date-parts":[[2005,8,16]]}}}